Reciprocal Role of ERK and NF-κB Pathways in Survival and Activation of Osteoclasts

Tsuyoshi Miyazaki,* Hideki Katagiri,‡ Yumi Kanegae,§ Hiroshi Takayanagi,* Yasuhiro Sawada,* Aiichiro Yamamoto,* Matthew P. Pando,i Tomoichiro Asano,‡ Inder M. Verma,i Hiromi Oda,* Kozo Nakamura,* and Sakae Tanaka*

*Department of Orthopaedic Surgery and ‡Third Department of Internal Medicine, Faculty of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan; §Laboratory of Molecular Genetics, Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108-8639, Japan; and iLaboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, California 92037

Abstract. To examine the role of mitogen-activated protein kinase and nuclear factor kappa B (NF-κB) pathways on osteoclast survival and activation, we constructed adenovirus vectors carrying various mutants of signaling molecules: dominant negative Ras (RasDN), constitutively active MEK1 (MEKCA), dominant negative IkB kinase 2 (IKKDN), and constitutively active IKK2 (IKKCA). Inhibiting ERK activity by RasDN overexpression rapidly induced the apoptosis of osteoclast-like cells (OCLs) formed in vitro, whereas ERK activation after the introduction of MEKCA remarkably lengthened their survival by preventing spontaneous apoptosis. Neither inhibition nor activation of ERK affected the bone-resorbing activity of OCLs. Inhibition of NF-κB pathway with IKKDN virus suppressed the pit-forming activity of OCLs and NF-κB activation by IKKCA expression upregulated it without affecting their survival. Interleukin 1α (IL-1α) strongly induced ERK activation as well as NF-κB activation. RasDN virus partially inhibited ERK activation, and OCL survival promoted by IL-1α. Inhibiting NF-κB activation by IKKDN virus significantly suppressed the pit-forming activity enhanced by IL-1α. These results indicate that ERK and NF-κB regulate different aspects of osteoclast activation: ERK is responsible for osteoclast survival, whereas NF-κB regulates osteoclast activation for bone resorption.

Key words: osteoclast • adenovirus • apoptosis • Ras • NF-κB

Introduction

Osteoclasts, multinucleated giant cells responsible for bone resorption, are terminally differentiated cells with a short life span. Recent findings suggest that the survival of osteoclasts is precisely regulated through interactions with supporting cells as well as by the action of several cytokines (Fuller et al., 1993; Jimi et al., 1995; Hughes et al., 1996; Selander et al., 1996; Kameda et al., 1997). However, the detailed molecular events implicated in these processes still remain elusive.

The small GTP-binding protein Ras is ubiquitously found in eukaryotic organisms and functions as an inducer of various intracellular signaling pathways including cell proliferation and differentiation (Bourne et al., 1990; Bollog and McCormick, 1991). This cascade can be activated by a variety of receptors (Chambard et al., 1987; L’Allemain et al., 1991; Ahn et al., 1992) and leads to activation of mitogen-activated protein kinase (MAPK) cascades. Upon stimulation, Ras as a GTP-bound form, and recruits the protein kinase Raf-1 to the plasma membrane, where the kinase can be activated (Leevers et al., 1994; Stokoe et al., 1994). Raf-1 stimulates MAP kinase kinases (MEK1 and MEK2), which in turn activate ERK1 (p44MAPK) and ERK2 (p42MAPK) (Kyriakis et al., 1992). A though the Ras/ERK pathway is reported to be an important component of cell survival sig-

A abbreviations used in this paper: α-MEM, α-modified minimum essential medium; CSF, colony stimulating factor; EMSA, electrophoretic mobility shift assay; ERK, extracellular signal-regulated kinase; IKK, IκB kinase; IL-1α, interleukin 1α; MA PK, mitogen-activated protein kinase; ME K, MAP kinase kinases (MEK1 and MEK2), which in turn activate ERK1 (p44MAPK) and ERK2 (p42MAPK) (Kyriakis et al., 1992). A though the Ras/ERK pathway is reported to be an important component of cell survival sig-

Downloaded from jcb.rupress.org on August 17, 2017
nal in hematopoietic cells (Kinoshiba et al., 1997), its exact role in osteoclasts has not been characterized. Nuclear factor kappa B (NF-κB) is a transcription factor that regulates the expression of many genes involved in immune and inflammatory responses (Siebenlist et al., 1994; Baldwin, 1996). A activation of NF-κB is controlled by sequential phosphorylation, ubiquitination, and degradation of its inhibitory subunit, IkB. A large multiprotein complex, the IkB kinase (IKK) signalosome, was found to contain a cytokine-inducible IkB kinase activity that phosphorylates IkB-α and IkB-β. The functional IKK complex contains IKK1 (IKKα), IKK2 (IKKβ), and IKK γ, and both IKK1 and IKK2 appear to make an essential contribution to IkB phosphorylation. Mercerio et al. (1997) reported that Ser177 and Ser181 to Glu mutant induced constitutive activation of NF-κB. It was recently reported that mice deficient in both the p50 and p52 subunits of NF-κB fail to generate mature osteoclasts and exhibit severe osteopetrosis (Frasnzo et al., 1997; Itozawa et al., 1997). Jimi et al. (1998) also reported the involvement of NF-κB pathways in the survival of osteoclasts promoted by interleukin 1 (IL-1). These results suggest that the NF-κB pathway is important for both the differentiation of osteoclast precursors and the survival of mature osteoclasts.

We recently reported that adenoviral vectors are useful for modulating osteoclast function by transducing foreign genes into osteoclasts (Tanaka et al., 1998). Using this system as well as specific inhibitors, we investigated the role of ERK pathways and NF-κB pathways in the survival and activation of osteoclasts, and found that the ERK activation is essential in maintaining osteoclast survival as is the NF-κB pathway for upregulation of bone-resorbing activity of osteoclasts.

Materials and Methods

Animals and Chemicals

Newborn ddY mice and 8-wk-old male ddY mice were purchased from Showa Laboratory Animal Center. α-M-modified minimum essential medium (αMEM) and DMEM were purchased from GIBCO BRL Life Technologies Inc., and FBS was purchased from Cell Culture Laboratory. Bacterial collagenase, 1x,25-dihydroxyvitamin D3 (1x,25(OH)2D3), and dispase from Godo Shusei Co. MEK inhibitor PD98059, anti-phospho-ERK and anti-IkB-α antibodies were purchased from New England Biolabs, Inc., anti-α- src antibody (clone 327) from Oncogene Research Products, anti-Flag antibody from Sigma Chemicals, and anti-NF-B (p65) antibody from Santa Cruz Biotechnology. Anti-FLAG, anti-MEK1, and anti-ERK antibodies were obtained from Transduction Laboratories. Other chemicals and reagents used in this study were of analytical grade.

Cells and Cell Cultures

Mouse primary osteoblastic cells were obtained from 1-d-old ddY mouse calvaria by enzymatic digestion, and bone marrow cells were from tibiae of 8-wk-old male ddY mice (Takahashi et al., 1988). Osteoblastic cells (5 x 10^6 cells/dish) were cocultured with bone marrow cells (10^5 cells/dish) on 10-cm dishes or collagen gel-coated dishes in the presence of 10 μM 1x,25(OH)2D3 and 1 μM PGE2 as previously reported (A katsu et al., 1992). For protein analysis, osteoclast-like cells (OCLs) were purified after a modification of the method originally reported by Tetzuka et al. (1992). In brief, the crude osteoclast preparation placed on plastic dishes was washed with αMEM, and treated with 5 ml of αMEM containing 0.1% collagenase and 0.2% dispase for 10 min to remove osteoblastic cells. The purity of OCLs and their precursors was >90% at the final preparation (Tanaka et al., 1995).

Constitutes and Gene Transduction

The recombinant adenovirus vector carrying either dominant negative Ras (Ser17 to Asn, A XRas), constitutively active MEK1 (Ser21B and Ser22 to Glu, A XM E K) or dominant negative IKK2 (also called IKKβ) (Ser177 and Ser181 to Ala, A xIKKβ), or constitutively active IKK2 (Ser177 and Ser181 to Glu, A xIKKβ) gene under the control of the CAG (cytomegalovirus IE enhancer + chicken β-actin promoter + rabbit β-globin poly (A)’ signal) promoter was constructed by homologous recombination between the expression cosmid cassette and the parental virus genome in 293 cells as described (Niwa et al., 1991; Miyake et al., 1996). The control virus (Ax1w1) was provided by Dr. Izumu Saito (The University of Tokyo, Bunkyo-ku, Tokyo, Japan). Titers of virus stocks were determined by endpoint cytopathic effect assay with the following modifications. 50 μl of DME/10%FBS was dispensed into each well of a 96-well tissue culture plate, and then eight rows of threefold serial dilutions of the virus starting from 10^-4 dilutions were prepared. 3 x 10^3 293 cells in 50 μl of DME/10%FBS was added to each well. The plate was incubated at 37°C in 5% CO2 in air, and 50 μl of DME/10%FBS was added to each well every 3 d. 12 d later, the endpoint of the cytopathic effect was determined by microscopy, and the 50% tissue culture infectious dose (TCID50) was calculated. One TCID50/ml approximately corresponds to one plaque forming unit (PFU/ml) (Kanegae et al., 1994). The efficiency of infection is affected not only by the concentration of viruses and cells, but also by the ratio of viruses to cells, the multiplicity of infection (MOI). In this study, MOI is expressed as a measure of titer how many PFU are added to every cell. Infection of adenovirus vectors to OCLs was carried out following the method previously described (Tanaka et al., 1998). In short, mouse cocultures on day 4, when OCLs began to appear, were incubated with a small amount of αMEM containing the recombinant adenoviruses for 1 h at 37°C at an indicated MOI. The cells were washed twice with PBS and further incubated with αMEM/10%FBS at 37°C. Experiments were performed 24 h after the infection.

Western Blotting

All extraction procedures were performed at 4°C or on ice. Cells were washed with ice-cold PBS, and then lysed by adding TNE buffer (1% NP-40, 10 mM Tris-HCl, pH 7.8, 150 mM NaCl, 1 mM EDTA, 2 mM NaVO4, 10 mM NaF, and 10 μg/ml aprotinin). The lysates were clarified by centrifugation at 15,000 rpm for 20 min. A n equal amount (20 μg) of protein was subjected to 8% SDS-PAGE under a reducing condition, transferred electrophoretically onto a nitrocellulose membrane, and probed sequentially with an appropriate primary antibody followed by secondary antibodies. Immunoreactive proteins were visualized using ECL Western blotting detection reagents (Amersham Co.) following the procedures recommended by the supplier. The blots were stripped by incubating for 20 min in stripping buffer (2% SDS, 100 mM 2-mercaptoethanol, 62.5 mM Tris-HCl, pH 6.7) at 50°C and reprobed by other antibodies.

Immunoprecipitation and In Vitro Kinase Assay

Treated cell cultures were washed twice with ice-cold PBS and lysed in lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 12 mM β-glycerophosphate, 5 mM EGTA, 0.5% deoxycholate, 3 mM DTT, 10 mM NaF, 1 mM Na3VO4, 2 μg leupeptin, 20 μg/ml aprotinin, and 1 mM PMSF). A 50 μl of protein A–agarose. A nter incubation for 1 h at 4°C with end-over-end mixing, the immune complex was recovered by centrifugation and washed with PBS (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 12 mM β-glycerophosphate, 5 mM EGTA, 0.5% deoxycholate, 3 mM DTT, 10 mM NaF, 1 mM Na3VO4, 2 μg leupeptin, 20 μg/ml aprotinin, and 1 mM PMSF). A 50 μl of protein sample was added to 50 μl of protein A-agarose (antibody (Santa Cruz Biotechnology) for 1 h, and then adding 20 μl of protein A-agarose. A nter incubation for 1 h at 4°C with end-over-end mixing, the immune complex was recovered by centrifugation and washed with washing buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EGTA, 2 mM DTT, and 1 mM PMSF) twice. Kinase activity was assayed by 15 min at 37°C in the presence of 6 μg substrate (MBP), 30 μM ATP, and 20 μCi [γ-32P]ATP in 55 μl assay buffer (20 mM Tris-HCl, pH 7.5, and 20 mM MgCl2). A nter completion of kinase assay, the protein was resolved by SDS-PAGE, and the gels were dried and subjected to autoradiography. The relative activity of ERK2 was quantified by measuring the radioactivity of phospho-Thioredoxin incorporated into MBP.
DNA Extraction and Electrophoretic Analysis

DNA was prepared and analyzed by gel electrophoresis according to the method described previously (Ijiri et al., 1998). In brief, purified OCLs were lysed by incubating at 60°C overnight in a digestion buffer containing 150 mM NaCl, 25 mM EDTA, 100 μg/ml proteinase K, and 0.2% SDS. The DNA was extracted twice with phenol/chloroform/isoamylalcohol and once with chloroform, and precipitated in ethanol with 350 mM CH₃COONa, pH 5.2. The DNA was dissolved in TE buffer (10 mM Tris-HCl, pH 8.0, and 1 mM EDTA) and treated with 20 μg/ml RNase A. The procedure for DNA extraction and precipitation were repeated. 2 μg of DNA was separated by electrophoresis on a 1.5% agarose gel and visualized by ethidium bromide staining with UV light illumination.

TUNEL Assay

Cells undergoing apoptosis were identified by means of the TdT-mediated dUTP-dioxigenin nick-end labeling (TUNEL) method, which specifically labels the 3'-hydroxyl terminal of DNA strand breaks. For the TUNEL procedure, all agents, including buffers, were a part of a kit (apoptosis in situ detection kit; Wako Pure Chemical Co.); the staining procedure was carried out according to the manufacturer’s recommendation. Negative controls included omission of TdT. Positive controls included treatment of the samples with DNase I. A apoptotic cells were recognized by their dark nuclear staining (TUNEL-positive), and nuclei of nonapoptotic cells were visualized by staining with methyl green.

Survival of OCLs

The survival rate was measured as reported (Ijiri et al., 1998). OCLs were purified 24 h after the infection and some of the cultures were subjected to tartrate-resistant acid phosphatase (TRAP) staining. Cell viability/survival was expressed as morphologically intact TRAP-positive multinucleated cells. Other cultures were further incubated for the indicated times, and then the number of living OCLs was counted. The number of viable cells remaining at the different time points is shown as a percentage of the cells at time zero.

Immunofluorescence Microscopy

For immunofluorescence analysis, cells were plated on sterile FBS-coated glass coverslips and purified by treatment with αMEM containing 0.1% collagenase and 0.2% disperse. After purification, OCLs were preincubated for 20 min at 37°C in αMEM without FBS and further incubated in αMEM with IL-1α (10 ng/ml) for indicated times, fixed in PBS containing 4% paraformaldehyde for 15 min, permeabilized with 0.2% Triton X-100 in PBS for 5 min, and then blocked with 3% skim milk in PBS for 20 min at room temperature. Cells were sequentially stained with anti-p65 antibody followed by Cy5-conjugated anti-rabbit IgG (Amersham Co.) as previously reported (Ishihiki et al., 1998). The subcellular localization of Cy5-labeled p65 was analyzed by a cooled CCD camera (Roper Scientific).

Electrophoretic Mobility Shift Assay

Nuclear extracts were prepared as described previously (Ijiri et al., 1998). For samples of purified OCLs, cells were scraped off each dish and put in ice-cold PBS. The cells were washed in ice-cold PBS, lysed for 10 min in ice-cold hypotonic buffer (buffer A: 10 mM Hepes, pH 7.9, 1.5 mM MgCl₂, 10 mM KCl, 0.5 mM EDTA, and 0.5 mM PM SF), and lysed for 10 min on ice in buffer A containing 0.1% NP-40. The lysates were centrifuged for 10 min at 12,000 g at 4°C for 10 min, supplemented with 5 mol of storage buffer (20 mM Hepes, pH 7.9, 100 mM KCl, 20% glycerol, 0.2 mM EDTA, 0.5 mM PM SF, and 0.5 mM DTT), and vortexed for 10 s. Lyzed nuclei were centrifuged for 10 min at 12,000 g, and the resulting supernatants were referred to as nuclear extracts. Oligonucleotide probes containing consensus sequences for NF-κB was pro-vided by Dr. J. Un-ichi-Inoue (The Institute of Medecal Science, The University of Tokyo, Minato-ku, Tokyo, Japan). The DNA binding reaction was performed at room temperature in a volume of 20 μl, which contained the binding buffer (25 mM Tris-HCl, pH 7.5, 1.5 mM EDTA, 7.5% glycerol, 75 mM NaCl, 1.5 mM DTT, 0.3% NP-40, and 1 mg/ml BSA), 1 μg of poly (dI-dC), 30 fmol of α-labeled probe, and 8 μg of nuclear proteins.

Results

Downregulation of Ras Inhibits Osteoclast Survival

Recently, we have reported that a replication-deficient adenovirus vector that contains a reporter gene encoding β-galactosidase efficiently infected human OCLs derived from human giant cell tumors and mouse OCLs formed in vitro (Tanaka et al. 1998). The proportion of β-gal-positive OCLs increased in accordance with the number of recombinant adenoviruses inoculated in the culture, and >85% of OCLs became strongly positive for β-gal activity at an MOI of 100, with no obvious morphological change or toxic effects. As shown in Fig. 1 A, the expression of RasDN was clearly induced in infected OCLs in an MOI-dependent manner. The bottom panel shows that an equal amount of protein was applied in each lane as determined by the Western blotting of c-Src. We next examined the effect of RasDN expression on the survival of OCLs. After the treatment with 0.1% collagenase and 0.2% dispase to remove osteoblastic cells, noninfected OCLs and OCLs infected with A x1w1 or A xAR asDN at an MOI of 100 were further incubated in αMEM containing 10% FBS to determine their survival. A fter the removal of osteoblastic cells, ~70% of OCLs infected with or without A x1w1 died within 18 h (Fig. 1, D and E). In contrast, almost all the RasDN-expressed OCLs disappeared within 18 h (Fig. 1, D and E), indicating a critical role of Ras in the survival of osteoclasts.

The Deteriorative Effect of RasDN Overexpression Is Reversed by AxMERK4+ Infection

We next examined the signaling pathways working downstream of Ras in osteoclasts. A shown in the top and middle panels of Fig. 1 C, overexpression of RasDN clearly inhibited the basal activity of ERK in OCLs and ERK activity was ~90% downregulated in RasDN-expressed OCLs at an MOI of 100. To determine whether or not...
modulating ERK activity could affect the survival of OCLs, we used PD 98059, a specific inhibitor of ERK activation that does not affect the activation of other MAPKs (Alessi et al., 1995; Favata et al., 1998). PD 98059 treatment severely diminished the survival of OCLs (Fig. 1 D). Conversely, upregulation of ERK activity in OCLs using recombinant adenovirus encoding constitutively active MEK1 (A x MEKCA) remarkably enhanced their survival (Fig. 1, B–E).

To examine whether or not ERK is the main signaling pathway working downstream of Ras in osteoclasts, we investigated the survival of OCLs that were coinfected with A x RasDN and A x MEKCA. Coinfected OCLs expressed RasDN and MEKCA at the similar level with the cells infected with either RasDN or MEKCA (Fig. 2 A), and the deteriorative effect of A x RasDN on OCLs was completely rescued by coinfection with A x MEKCA (Fig. 2 B). Nor did the treatment with PD 98059, which suppresses the intrinsic MEK activation, inhibit the survival of MEKCA-expressed OCLs (Fig. 2 B). We also found that the expression of RasDN did not alter the activity of JNK/SAPK or p38 in OCLs (data not shown). Taken together, these findings clearly demonstrate that the Ras/ERK pathway is an important component of survival signal in osteoclasts.

RasDN Expression Causes Apoptosis of Osteoclasts

We next determined if the reduction of OCL survival by expression of RasDN was due to apoptosis. After purification, uninfected OCLs or OCLs infected with A x1w1, A x RasDN, or A x MEKCA at an MOI of 100 were cultured for 12 or 24 h. The cells were harvested, and genomic DNA was isolated and resolved on 1.5% agarose gel. After 12 h of culturing, DNA fragmentation was hardly detectable in uninfected OCLs or OCLs infected with A x1w1, whereas OCLs infected with A x RasDN clearly showed DNA fragmentation (Fig. 3 A). This fragmentation was observed even in uninfected OCLs or OCLs infected with A x1w1 after 24 h of culture, and the expression of MEKCA markedly inhibited the fragmentation (Fig. 3 A). A lmost all the nuclei of MEKCA-expressed OCLs, 24 h after the purification, were stained uniformly with Hoechst 33258, which indicates that the cells were alive and the nuclei.
were intact, whereas expression of RasDN caused condensation of >80% of nuclei 12 h after purification (Fig. 3B).

We further determined that ~80% of the nuclei infected with AxRasDN underwent apoptosis 12 h after the purification as shown in Fig. 3C by TUNEL staining. In contrast, positive TUNEL staining was hardly observed in MEKCA-expressed OCLs even 24 h after the purification (Fig. 3C). These findings suggest that Ras/ERK pathways contribute greatly to preventing apoptosis of osteoclasts.

**IL-1α Activates ERK in OCLs**

IL-1α is a proinflammatory cytokine that strongly promotes the survival of osteoclasts by preventing their apoptosis (Jimi et al., 1998). Therefore, we examined the effect of IL-1α treatment on ERK activity in OCLs. After purification, Ax1w1-infected OCLs and RasDN-expressed OCLs were preincubated for 20 min at 37°C in αMEM without FBS and further incubated in αMEM with IL-1α (10 ng/ml) for various periods. As shown in the top panel of Fig. 4A,

Figure 3. RasDN expression stimulates apoptosis of OCLs. (A) DNA ladder assay for apoptosis. Fragmentation of DNA in uninfected OCLs and OCLs infected with Ax1w1 was not detectable within 12 h, but it was observed after culturing for 24 h. DNA fragmentation was observed in RasDN-expressed OCLs within 12 h. In contrast, expression of MEKCA inhibited ladder formation of DNA. The 123-bp ladder DNA was used as a marker. (B) The nuclei of MEKCA-expressed OCLs 24 h after the purification were stained uniformly with Hoechst 33258 (bottom), whereas expression of RasDN caused fragmentation and condensation of nuclei 12 h after the purification (top). (C) The TUNEL staining of MEKCA- or RasDN-expressed OCLs was started 24 or 12 h after the purification, respectively. Apoptotic cells were recognized by their dark nuclear staining (TUNEL-positive) and nuclei of nonapoptotic cells were visualized by staining with methyl green. Bars: (B) 10 μm; (C) 100 μm.

Figure 4. The effects of IL-1α treatment on RasDN-expressed OCLs. (A, top) Time course of change in ERK activity in Ax1w1- or AxRasDN-infected OCLs in response to IL-1α treatment. (middle) Western blot analysis of the expression of ERK protein. (bottom) Time course of change in the protein level of IκB in Ax1w1- or AxRasDN-infected OCLs. (B) Effects of AxRasDN on the survival of OCLs promoted by IL-1α. After purification, Ax1w1- or AxRasDN-infected OCLs were incubated with αMEM/10%FBS in the presence of IL-1α (10 ng/ml) for indicated times. The number of viable cells remaining at different time points is shown as a percentage of the cells at time zero. AxRasDN partially inhibited the promotion of OCL survival induced by IL-1α. (C) Ax1w1- or AxRasDN-infected OCLs were incubated with 10 ng/ml IL-1α for indicated time periods. Equivalent amounts of nuclear extract protein were incubated with a radiolabeled probe containing NF-κB binding site. Activation of NF-κB was determined using EMSA. (D) Purified Ax1w1-infected OCLs or RasDN-expressed OCLs were treated with IL-1α (10 ng/ml) for 0 or 30 min. Cells were fixed and incubated with antibodies against p65 followed by Cy5-conjugated anti-rabbit immunoglobulins. The subcellular localization of Cy5-labeled p65 (red) was observed by a cooled CCD camera. To visualize the nuclei of the OCLs, the cells were further stained with Hoechst 33258 (blue). Before stimulation, p65 was localized in the cytoplasm, especially around the nuclei of OCLs infected with Ax1w1 or AxRasDN. At 30 min, p65 was detected in most of the nuclei of Ax1w1- or AxRasDN-infected OCLs in response to IL-1α.
IL-1α stimulated a rapid and transient increase in ERK activity in OCLs. ERK activation in response to IL-1α was transient, reaching the highest level after 15–30 min of stimulation and returning to the basal level after 60 min. Stimulation of ERK activity was not accompanied by a change in the expression of ERK protein (Fig. 4 A, middle). As previously reported by Jimi et al. (1998), IL-1α treatment strongly promoted the survival of OCLs (Fig. 4 B). Interestingly, the expression of RasDN in OCLs only partially inhibited the ERK stimulation induced by IL-1α, as shown in the top panel of Fig. 4 A, and partially suppressed the promotion of their survival induced by IL-1α (Fig. 4 B).

**RasDN Expression Does Not Affect the IL-1α-induced Nuclear Translocation of NF-κB in OCLs**

Because activation of NF-κB was reported to be involved in the survival of osteoclasts promoted by IL-1α (Jimi et al., 1998), we examined the effect of RasDN protein on the activation of NF-κB in response to IL-1α. NF-κB is present in the cytosol in an inactive state, complexed with the inhibitory IκB proteins. Activation occurs via phosphorylation of IκB-α at Ser 32 and 36, which promotes the degradation of IκB-α, resulting in the dissociation and nuclear translocation of active NF-κB (Traenckner et al., 1995; Chen et al., 1996). As shown in the bottom panel of Fig. 4 A by Western blotting, IκB-α expression rapidly decreased upon IL-1α stimulation and returned to the basal level after 60 min of stimulation in A x1w1-infected OCLs. The bottom panel of Fig. 4 A shows that RasDN expression in OCLs did not affect the kinetics of the degradation of IκB-α by IL-1α. The change in the localization of NF-κB in OCLs treated with IL-1α was also examined immunocytochemically using specific antibodies against the p65 subunit of NF-κB. Before stimulation, p65 was diffusely distributed throughout the cytoplasm. Consistent with the previous report (Jimi et al., 1998), when purified A x1w1-infected OCLs were treated with IL-1α for 30 min, p65 was detected in most nuclei of the cells. Overexpression of RasDN did not affect the kinetics of nuclear translocation of NF-κB in OCLs (Fig. 4 D). Consistent with the results of the immunocytochemistry, electrophoretic mobility shift assay (EMSA) showed that NF-κB binding activity was not impaired in RasDN-overexpressed OCLs (Fig. 4 C).

**Modulation of NF-κB Activity Did Not Affect the Survival of OCLs**

To further examine the role of NF-κB pathway in osteoclasts, we constructed adenovirus vectors encoding dominant negative I KK2 (I KK2DN) and constitutively active I KK2 (I KK2CA) with Flag tag, and investigated their effects on OCLs. Fig. 5 A demonstrates the clear induction of I KK2DN and I KK2CA in infected OCLs in an MOI-dependent manner. Fig. 5 B shows that the degradation of I kB-α induced by IL-1α treatment was strongly blocked by I KK2DN expression. Immunocytochemical studies showed that I KK2DN expression inhibited nuclear translocation of p65 in IL-1α-stimulated OCLs (Fig. 5 D), and <25% of the nuclei of OCLs were positively stained for p65 even after 30 min of IL-1α stimulation. In contrast, >60% of the nuclei of AxIKK2CA-infected OCLs were positively stained without any stimulation (Fig. 5 D). EMSA demonstrated that NF-κB activation was inhibited in I KK2DN-expressed OCLs treated with IL-1α. Conversely, slight constitutive NF-κB activation was observed in I KK2CA-expressed OCLs (Fig. 5 C). As shown in Fig. 6, neither I KK2DN nor I KK2CA virus infection significantly changed the survival of OCLs with or without IL-1α stimulation.

![Figure 5](https://jcb.rupress.org/jcb/article-pdf/148/6/338/4223647/148-338.pdf)
NF-κB Pathway Is Involved in Osteoclast Activation for Bone Resorption

We next examined the role of ERK pathways and NF-κB pathways on bone-resorbing activity of OCLs using the adenovirus vectors described above. This activity of OCLs was quantified by measuring the pit area formed on dentine slices as previously reported (Tamura et al., 1993). To minimize the influence of the different survival periods on the pit formation by OCLs, we performed the pit assay after 12 h of culturing and the pit-forming activity is expressed as the area resorbed per osteoclast. As shown in Fig. 7 A, neither RasDN nor MEKCA expression altered the pit-forming activity of OCLs, indicating that the ERK pathway is not involved in the bone-resorbing activity of the individual OCL. In contrast, OCL pit-forming activity was significantly inhibited by induction of IKKDN, whereas overexpression of IKKCA enhanced it. Because IL-1α strongly promotes not only the survival of osteoclasts, but also their bone resorbing activity (Boyce et al., 1989), we examined the effect of IKKDN expression on the bone-resorbing activity promoted by IL-1α. As shown in Fig. 7 B, IL-1α treatment strongly enhanced the OCL pit-forming activity, and inhibiting NF-κB activation by the IKKDN virus significantly suppressed the pit-forming activity enhanced by IL-1α.

Colony-stimulating Factor 1 (CSF-1) Activates ERK, but Not NF-κB in OCLs

Because CSF-1 (also called macrophage colony-stimulating factor) has been reported to prolong the survival of OCLs without upregulating their bone resorbing activity, we examined the effect of CSF-1 treatment on ERK and NF-κB activity in OCLs. As shown in the top panel of Fig. 8 A, ERK activation in response to CSF-1 was transient, reaching the highest level after 2–15 min of stimulation and returning to the basal level after 60 min. Stimulation of ERK activity was not accompanied by a change in the expression of NF-κB.

---

**Figure 6.** The effect of IKKDN and IKKCA expression on the survival of OCLs. After purification, OCLs infected Ax1w1, Ax-IKKDN, or AxiKKCA were incubated with αMEM/10% FBS and Ax1w1- or AxiKKDN-infected OCLs were incubated in the presence of IL-1α (10 ng/ml) for the indicated times. The number of viable cells remaining at the different time points is shown as a percentage of the cells at time zero.

**Figure 7.** Dentine-resorbing activity of OCLs expressing RasDN, MEKCA, IKKDN, or IKKCA. (A) OCLs 24 h after the infection were restored by digesting the collagen gel with 0.2% collagenase for 20 min at 37°C and an aliquot of the crude OCL preparation was transferred onto dentine slices (Ø 5 mm) as well as on 96-well culture plates and further cultured for 12 h. The resorbed area on dentine slices was measured using an image analysis system, and the number of TRAP-positive OCLs on culture plates was counted by light microscopy. The bone-resorbing activity of the cells was expressed as the resorbed area per osteoclast. The values are means ± SD (n = 8). (one asterisk) Significantly less than control, P < 0.05. (two asterisks) Significantly greater than control, P < 0.005. (B) After the transfer onto dentine slices, Axi1w1- or Axi-IKKDN-infected OCLs were further incubated for 12 h in the presence or absence of IL-1α (10 ng/ml). The pit-forming activity of Axi1w1-infected OCLs treated with IL-1α was significantly lower than that of Axi1w1-infected OCLs treated with IL-1α (#P < 0.01). The values are means ± SD (n = 8). ##Significantly greater than Axi1w1-infected OCLs without IL-1α stimulation, P < 0.01.

**Figure 8.** The effects of CSF-1 treatment on OCLs. (A, top) Time course of change in ERK activity in OCLs after stimulation with CSF-1 (100 ng/ml). (middle) Western blot analysis of the expression of ERK protein. (bottom) Time course of change in the protein level of IκB-α in CSF-1–treated OCLs. (B) OCLs were incubated with CSF-1 for indicated time periods. Equivalent amounts of nuclear extract protein were incubated with a radiolabeled probe containing the NF-κB binding site. A titration of NF-κB was determined using EMSA. IL-1α–treated OCLs (right lane) were used as positive controls (PC). (C) After purification, OCLs were incubated with αMEM/10% in the presence or absence of CSF-1 for the indicated times. The activation of NF-κB was determined using EMSA. IL-1α–treated OCLs (right lane) were used as positive controls (PC). (D) After the transfer onto dentine slices, OCLs were further incubated for 12 h in the presence or absence of CSF-1 (100 ng/ml). CSF-1 stimulation did not alter the OCL pit-forming activity. The values are means ± SD (n = 8).
expression level of ERK protein (Fig. 8 A, middle). As previously reported (Fuller et al., 1993; Jimi et al., 1995), CSF-1 treatment strongly promoted the survival of OCLs (Fig. 8 C). On the other hand, CSF-1 did not alter the expression level of IκB-α (Fig. 8 A, bottom) and activate NF-κB (Fig. 8 B). In addition, OCL bone-resorbing activity remained unchanged despite CSF-1 stimulation (Fig. 8 D). These results strongly support our findings that ERK and NF-κB pathways are involved in osteoclast survival and activation for bone resorption, respectively.

Discussion

The Ras superfamily of GTPases is implicated in a number of physiological processes including cell proliferation and differentiation, and plays important roles in the organization of cellular architecture and regulation of membrane dynamism in addition to cell cycle control (Bourne et al., 1990; Bollag and McCormick, 1991; Kaziro et al., 1991). Recently, Luckman et al. (1998) reported that the nitrogen-containing bisphosphonates alendronate, ibandronate, and risedronate, which cause apoptosis in osteoclasts and suppress their bone-resorbing activity, inhibit posttranslational modification (prenylation) of proteins with farnesyl or geranylgeranyl isoprenoid groups, including the Ras superfamily of GTPases. Further studies performed by Fisher et al. (1999) demonstrated that alendronate acts directly on osteoclasts and interferes with the generation of geranylgeranyl diphosphate by inhibiting enzymes in the cholesterol biosynthesis pathway, resulting in the suppression of osteoclast function. These findings suggest the critical role of the Ras superfamily in this function.

The pleiotropic functions of the Ras protein are now explained by its capability to activate multiple downstream pathways (Koide et al., 1993; Moodie et al., 1993; Rodriguez-Viciana et al., 1994; Van Aelst et al., 1993, 1994; Voigt et al., 1993). One of the most important signaling cascades lying downstream of Ras is the MAPK cascade, which is activated via the Ras–Raf interaction. This interaction induces the membrane translocation and activation of Raf, and activated Raf phosphorylates tyrosine/threonine kinase MEK, which in turn phosphorylates ERK. In the present study, we demonstrated the essential role of Ras/ERK pathways in the survival of osteoclasts. First, adenovirus vector carrying a dominant negative mutant of Ras (A xRasDN) suppressed ERK activity in OCLs and promoted the apoptosis of OCLs. A similar effect was observed using a MEK inhibitor, PD90859. Second, expression of constitutively active MEK1-induced sustained stimulation of ERK in OCLs and dramatically promoted their survival, and the apoptosis-inducing effect of A xRasDN was completely rescued by coinfection with A xMEKCA. Finally, IL-1α, which strongly promotes OCL survival, rapidly stimulates ERK activation in OCLs. It should be noted that overexpression of RasDN only partially inhibited the ERK activation and suppressed the prolonged survival induced by IL-1α, whereas PD90859 strongly eliminated the effect of IL-1α (data not shown), suggesting that IL-1α stimulates ERK activity via Ras-independent pathways as well. These results clearly demonstrate that ERK activation is indispensable for the survival of osteoclasts, and that Ras is at least partially involved in this process.

It remains elusive how ERK activation stimulates OCL survival. In fibroblasts, ERK activation is followed by phosphorylation of transcription factors and induction of immediate early gene expression. The dimeric transcription factor A P-1 (activator protein-1) is a major target of cell growth, differentiation, and stress signaling pathways (Angel and Karin, 1991; Karin and Hunter, 1995; Whitmarsh and D avis, 1996). A P-1 consists of various combinations of Fos and Jun family members that dimerize via a leucine zipper domain and bind to DNA via an adjacent TATA box region (Landschulz et al., 1988; Gentz et al., 1989; Kozarides and Ziff, 1989). The Fos family consists of four gene products (c-Fos, FosB, Fra-1, and Fra-2), whereas the Jun family is made up of three gene products (c-Jun, JunB, and JunD). We also found that sustained stimulation of ERK in OCLs by MEKCA expression as well as IL-1α stimulation increased c-Fos, Fra-2, c-Jun, and JunB expression (data not shown), suggesting that A P-1 activation may be involved in the survival signaling in osteoclasts. Further study will be necessary to elucidate the detail of osteoclast survival signaling.

Jimi et al. (1998) recently reported that the activation of NF-κB is involved in the survival of osteoclasts promoted by IL-1α. They clearly showed the nuclear translocation of NF-κB and degradation of IκB in OCLs in response to IL-1α treatment. The survival of OCLs supported by IL-1α was suppressed by pretreatment with proteasome inhibitors, which inhibits NF-κB activation by preventing IκB degradation, or with antisense oligonucleotides to NF-κB components (Jimi et al., 1998). In contrast to their results, we were unable to show the effect of NF-κB on the survival of OCLs. Consistent with the previous report, IL-1α treatment induced rapid nuclear translocation of NF-κB in OCLs and degradation of IκB. However, overexpression of neither RasDN nor MEKCA changed the localization of NF-κB in the presence or absence of IL-1α. In addition, either inhibition of NF-κB activity by overexpression of dominant negative IKK (IKKDN) or sustained activation of NF-κB by transducing constitutively active IKK (IKKCA) had little effect on the survival of OCLs with or without IL-1α stimulation. We cannot fully explain the reason for the discrepancy between our results and those of the previous report, but it is possible that proteasome inhibitors and antisense oligonucleotides may possess some undesirable effects on OCLs unrelated to NF-κB inhibition.

However, NF-κB has an important role in the bone-resorbing activity of osteoclasts because adenovirus vector-induced IKKDN expression significantly suppressed the pit-forming activity of OCLs and IKKCA expression enhanced it, although these two viruses had no effect on OCL survival. Members of the TNF receptor family and the IL-1 receptor associated either directly or indirectly with TNF receptor-associated factors (TRAFs), adaptor proteins that recruit and activate downstream signaling transducers (Rothe et al., 1994). TRAF6 is a newly identified member of TRAF, which is not involved in TNF signaling but in IL-1 signaling (Cao et al., 1996; Darnay et al., 1998; Gailibert et al., 1998). Not only does TRAF6 activate NF-κB by signaling via NIK and IKK, but it also activates ERK in a Ras-independent manner (Kashppark et al., 1998). A recent study on TRAF6 knockout mice demon-
strated the essential role of TRAF6 in the activation of osteoclasts (Lomaga et al., 1999). Taken together, it is likely that IL-1α can promote survival and activity of osteoclasts simultaneously via ERK and NF-κB activation, both of which are mediated by TRAF6. Our present study proposes the reciprocal role of ERK and NF-κB pathways in the survival and activation of osteoclasts. Further investigation of these pathways in osteoclasts will give us new insight into the molecular mechanism regulating bone resorption.

R. Yamaguchi (Department of Orthopaedic Surgery, The University of Tokyo) provided expert technical assistance. We thank I. Saito, J. Miyazaki, and J.-I. Inoue (The Institute of Medical Science, The University of Tokyo) for gifts of the recombinant adenosine vector system, the CA G promoter, and the NF-κB binding oligonucleotide, respectively.

This work was in part supported by a grant from the Japan Orthopaedic and Traumatology Foundation Inc. (No. 0089; Alcare Award) and the Japanese Society for the Promotion of Sciences (Grant-in-Aid 11770200).

References

Ahn, N.G., D.J. Robbins, J.W. Haycock, R. Seger, M.H. Cobb, and E.G. Krebs. 1995. PDGF receptor tyrosine kinase as a converging target for different growth factor signaling pathways: use of pertussis toxin as a discrimination factor. Cell Regul. 6:269–276.

Ansel, P., and M. Karin. 1996. The role of Jun, Fos, and the A-P-1 complex in cell proliferation and transformation. Biochem. Biophys. Acta. 1270:129–157.

Balduin, A.S., Jr. 1996. The NF-κB and IκB proteins: new discoveries and insights. Annu. Rev. Immunol. 14:649–683.

Boye, F.C. 1996. NF-κB activation: signal transduction from the cell surface to the nucleus. Curr. Biol. 6:574–577.

Boyce, B.F., T.B. Aufdemorte, I.R. Garrett, A.J. Yates, and G.R. Mundy. 1989. Estrogen promotes apoptosis of murine osteoclasts mediated by TNF-R1. J. Biol. Chem. 264:7899–8005.

Boyce, B.F., and J.R. Schwartz. 1989. The osteoclast in bone resorption: a review. J. Exp. Med. 169:1517–166.

Browning, R., J. L’Allemain, G. Pouyssegur, and M.J. Weber. 1991. p42/mitogen-activated protein kinase pathway and prevent post-translational prenylation of GTP-binding proteins. J. Biol. Chem. 266:17906–17912.

Cao, Z., J. Xiong, M. Takeuchi, T. Kurama, and D.V. Goeddel. 1996. TRAF6 is a signal transducer for interleukin-1. Nature. 383:443–446.

Chambard, J.-C., P. Sarid, G. L’aimein, and J. Pouysségur. 1987. Two growth factor signalling pathways in fibroblasts distinguished by pertussis toxin. Nature. 326:800–803.

Chen, Z.J., L. Parent, and T. Maniatis. 1996. Site-specific phosphorylation of IκBα by a novel ubiquitination-dependent protein kinase activity. Cell. 84:835–862.

Darnay, B.G., V. Haridas, J. Ni, P.A. Moore, and B.B. Aggarwal. 1998. Characterization of the intracellular domain of receptor activator of NF-κB (RANK). Interaction with tumor necrosis factor receptor-associated factor 6 (TRAF6) stimulates extracellular signal-regulated kinase (ERK) activity in CD40 signaling along a Ras-independent pathway. J. Exp. Med. 187:237–244.

Darnay, B.G., V. Haridas, J. Ni, P.A. Moore, and B.B. Aggarwal. 1998. Characterization of the intracellular domain of receptor activator of NF-κB (RANK). Interaction with tumor necrosis factor receptor-associated factor 6 (TRAF6) stimulates extracellular signal-regulated kinase (ERK) activity in CD40 signaling along a Ras-independent pathway. J. Exp. Med. 187:237–244.

Favata, M.F., K.Y. Horiuchi, E.J. Manos, A.J. Daulerio, D.A. Stradley, W.S. Young, M. Barbosa, M. Mann, A. Manning, and A. Rao. 1997. IKK-1 and IKK-2: cytokine-activated IκB kinases. Nature. 385:417–421.

Favata, M.F., K.Y. Horiuchi, E.J. Manos, A.J. Daulerio, D.A. Stradley, W.S. Young, M. Barbosa, M. Mann, A. Manning, and A. Rao. 1997. IKK-1 and IKK-2: cytokine-activated IκB kinases. Nature. 385:417–421.

Favata, M.F., K.Y. Horiuchi, E.J. Manos, A.J. Daulerio, D.A. Stradley, W.S. Young, M. Barbosa, M. Mann, A. Manning, and A. Rao. 1997. IKK-1 and IKK-2: cytokine-activated IκB kinases. Nature. 385:417–421.
kDa tumor necrosis factor receptor. Cell. 78:681–692.
Selander, K.S., P.L. Harkonen, E. Valve, J. Monkkonen, R. Hannuniemi, and H.K. Vaananen. 1996. Calcitonin promotes osteoclast survival in vitro. Mol. Cell. Endocrinol. 122:119–129.
Siebenlist, U., G. Franzoso, and K. Brown. 1994. Structure, regulation and function of NF-kappa B. Annu. Rev. Cell Biol. 10:405–455.
Stokoe, D., S.G. Macdonald, K. Cadwallader, M. Symons, and J.F. Hancock. 1994. A cistivation of Raf as a result of recruitment to the plasma membrane. Science. 264:1463–1467.
Takahashi, N., T. A katsu, N. U dagawa, T. Sasaki, A. Yamaguchi, J. M. Moseley, T. J. Martin, and T. Suda. 1988. Osteoblastic cells are involved in osteoclast formation. Endocrinology. 123:2600–2602.
Tamura, T., N. Takahashi, T. A katsu, T. Sasaki, N. U dagawa, S. Tanaka, and T. Suda. 1993. New resorption assay with mouse osteoclast-like multinucleated cells formed in vitro. J. Bone Miner Res. 8:953–960.
Tanaka, S., N. Takahashi, N. U dagawa, H. Murakami, I. Nakamura, T. Kurokawa, and T. Suda. 1995. Possible involvement of focal adhesion kinase, p125FAK, in osteoclastic bone resorption. J. Cell Biochem. 58:424–435.
Tanaka, S., T. Takahashi, H. Takayanagi, T. Miyazaki, H. Oda, K. Nakamura, H. Hirai, and T. Kurokawa. 1998. Modulation of osteoclast function by adenovirus vector-induced epidermal growth factor receptor. J. Bone Miner Res. 13:1714–1720.
Tezuka, K., T. Sato, H. Kamioka, P.J. Nijweide, K. Tanaka, T. Matsuo, M. O hta, N. Kurihara, Y. Hakeda, and M. Kume gawa. 1992. Identification of osteopontin in isolated rabbit osteoclasts. Biochem. Biophys. Res. Commun. 186:911–917.
Traenckner, E.B., H.L. Pahl, T. Henkel, K.N. Schmidt, S. Wilk, and P.A. Ba euerle. 1995. Phosphorylation of human IxB on serines 32 and 36 controls IxB proteolysis and NF-kB activation in response to diverse stimuli. EMBO (Eur. Mol. Biol. Organ.) J. 14:2876–2883.
Van A elst, L. M. Barr, S. Marcus, A. Polverino, and M. Wigler. 1993. Complex formation between RAS and RAF and other protein kinases. Proc. Natl. Acad. Sci. USA. 90:6213–6217.
Van A elst, L., M.A. White, and M.H. Wigler. 1994. R as partners. Cold Spring Harb. Symp. Quant. Biol. 59:181–186.
Vojtek, A. B., S.M. Hollenberg, and J.A. Cooper. 1993. Mann shal R as interacts directly with the serine/threonine kinase Raf. Cell. 74:205–214.
Whitmarsh, A. J., and R. J. D avis. 1996. Transcription factor A P-1 regulation by mitogen-activated protein kinase signal transduction pathways. J. Mol. Med. 74:589–607.